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Introduction
Peritoneal cancer (PC) is a challenging pathology to diagnose and treat. Without therapeutic management, expected sur-
vival time is <6 months for PC of  colorectal origin or primitive diseases of  the peritoneum (1-3). Palliative systemic che-
motherapy has a 5-year survival of  <15% due to low penetration of  the agents and a high incidence of  complications. 
Since 1990, hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with cytoreductive surgery (CRS) has 
improved outcomes, and the median survival time of  patients increased to 22.9 months in a selected cohort of  patients 
(4-6). However, CRS+HIPEC is associated with significant morbidity and mortality rates (42% and 3.8%, respectively), 
even in specialist referral centres, and quality of  life (QoL) is impaired for months after the procedure (4, 7, 8). There-
fore, only patients in good general condition can be considered for this treatment. Furthermore, HIPEC has important 
pharmacokinetic limitations, namely single-dose administration and poor distribution and tissue penetration (9).
Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is a new type of  intraperitoneal drug delivery which over-
comes some of  the above limitations (10). It consists of  an intraperitoneal application of  vaporised aerosol chemo-
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Anaesthesia in a Toxic Environment: 
Pressurised Intraperitoneal Aerosol 
Chemotherapy: A Retrospective Analysis
Abstract
Objective: Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is a new type of  intraperitoneal chemotherapy for peritoneal carcinosis 
via minimally invasive surgery. This technique’s specificity is the remote application of  the therapy because of  the potential risk of  exposure to 
toxic products. The present paper summarises the important aspects of  PIPAC and analyses the anaesthetic outcomes. 
Methods: This retrospective study included all patients undergoing PIPAC treatment between January 2015 and February 2018. Data on pro-
tocol adherence and perioperative anaesthetic complications and postoperative nausea and vomiting (PONV) and pain levels (visual analogue 
scale 0–10) from recovery room to 72 h were analysed. 
Results: The overall analysis included 193 PIPAC procedures on 87 patients. Protocol adherence was high as regards the use of  propofol 
(100%), rocuronium (98%), antiemetic prophylaxis (99%) and lidocaine intravenous (i.v.) (87%). No accidental exposure to chemotherapy oc-
curred during the study period. Of  the 87 patients, 6.3% suffered delayed recovery, 58% due to hypothermia and 42% due to excessive sedation 
or curarisation. In the recovery room, 16% of  patients suffered moderate to severe pain, requiring >8 mg of  morphine i.v., with average doses of  
13.7 mg. Median postoperative pain scores were 1 and 3 at 12 h and 0 and 0 at 72 h at rest and mobilisation, respectively. PONV was observed 
in <10% of  patients during the first 12 h, but in 40% at 72 h.
Conclusion: A dedicated anaesthetic protocol and intraoperative safety checklist facilitates safe, well-tolerated anaesthesia for PIPAC treatments.
Keywords: Adverse effects, doxorubicin, laparoscopy, peritoneal metastases, pressurised intraperitoneal chemotherapy
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therapy via minimally invasive surgery using a specific nebu-
liser (CapnoPen®). This approach has been shown to improve 
distribution and tissue penetration considerably (10-12). 
Furthermore, PIPAC can be applied repeatedly, thus increas-
ing the potential to achieve local control of  recurrent PC and 
allowing sequential tumour sampling during laparoscopy. 
Moreover, chemotherapy doses applied during PIPAC are 
approximately 10 times smaller than systemic chemotherapy, 
thus reducing systemic exposure (13).
The present recommendations are for three applications of  
PIPAC over 3 months. The chemotherapy regimens current-
ly proposed are oxaliplatin alone for colorectal cancer and 
doxorubicin and cisplatin for PCs of  other origins. Platinum 
agents may induce anaphylactic reactions and can irritate the 
eyes, skin and airways; they are toxic to the kidneys and bone 
marrow (14, 15). Doxorubicin provokes mucosal inflamma-
tion, leukopenia and dilated cardiomyopathy. Both cytotoxic 
drugs are carcinogenic to humans (class 2A according to the 
International Agency for Research on Cancer) (16-19).
Owing to the potential leaks of  aerosolised cytostatics, a 
special safety protocol is needed to reduce exposure risks to 
healthcare staff. The currently proposed protocol involves 
the remote administration of  chemotherapy, with no direct 
access to the patient for approximately 30 min. This is partic-
ularly challenging for an anaesthesiology team as it requires 
adaptations to standard protocols for comparable procedures 
regarding invasiveness and duration, such as laparoscopic 
cholecystectomy.
Therefore, the aim of  the present study was to summarise 
the important aspects of  this particular procedure from the 
anaesthetic point of  view and analyse anaesthetic outcomes.
Methods
This retrospective analysis included all consecutive patients 
undergoing PIPAC at Lausanne University Hospital between 
January 2015 and February 2018. All patients were discussed 
at multidisciplinary tumour boards, and typical indications 
were isolated peritoneal disease in patients not amenable to 
CRS+HIPEC.
The study was approved by Lausanne University Hospital’s 
Institutional Review Board (no. 2016-00274) and conducted 
and reported in compliance with the STROBE criteria and 
registered online (http://www.researchregistry.com; UIN: 
4332). All patients were asked for consent to the use of  their 
anonymised clinical data, via a general consent form, as per 
Swiss law. Patients refusing to sign the form were excluded 
from the study.
Anaesthetic protocols and an intraoperative safety checklist 
and procedure were designed in close collaboration with the 
surgical team before the study started (20). The anaesthetic 
protocol and safety checklist are provided as an online Ap-
pendix 1. 
Safety considerations
During the study period, the same surgeon was supported by 
a dedicated team of  anaesthesiologists and instrument tech-
nicians for all the PIPAC procedures. Owing to the adminis-
tration of  a carcinogenic chemotherapy, pregnant or breast-
feeding women were not allowed to enter the operating room 
(OR). 
Pressurised intraperitoneal aerosol chemotherapy was per-
formed in an OR with a laminar flow, as per safety proto-
col. Before the vaporisation phase, the surgeon and the entire 
team run through the safety checklist. During and after the 
administration phase, healthcare staff must wear a high fil-
tration face mask (FFP3), surgical gown, double nitrile gloves 
and protective glasses to avoid exposure to the skin and muco-
sa in case of  accidental exposure when entering the OR. With 
these precautions, entry into the OR due to an anaesthetic 
problem is allowed if  urgently required. 
PIPAC procedure
The procedure lasts approximately 90 min and is techni-
cally comparable to laparoscopic cholecystectomy (Figure 
1). Laparoscopy is performed using a standard pressure of  
12 mmHg (CO2 pneumoperitoneum) using two balloon tro-
cars (21). The first part of  the procedure involves an evalu-
ation of  the disease extent using the PC index (22). Perito-
neal biopsies are obtained, and ascites is removed from the 
abdominal cavity. Chemotherapy is then vaporised using a 
high-pressure injector connected to a nebuliser that was de-
Figure 1. Diagram of  pressurised intraperitoneal aer-
osol chemotherapy. The abdominal cavity is accessed 
using two balloon trocars, which create a hermetic seal. 
Liquid chemotherapy is dispersed as an aerosol by us-
ing a standard injector and a specific nebuliser (21)
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veloped specifically for PIPAC. The injector is remote-con-
trolled, allowing the staff to be outside the OR during the 
administration of  intraperitoneal chemotherapy. The drugs 
are vaporised for 5 min, and then therapeutic CO2 pneumo-
peritoneum is maintained for 30 min to allow drug penetra-
tion into the tissues. At the end of  the procedure, the pneu-
moperitoneum is exsufflated via the closed aerosol waste 
system through two sequential microparticle filters into the 
anaesthetic air waste system. 
Anaesthetic considerations
PIPAC patients are given general anaesthesia with standard 
tracheal intubation. Owing to the patient’s inaccessibility 
during the vaporisation phase, monitoring must be possible 
from outside the OR to allow remote-controlled drug injec-
tion if  needed.
Positioning and monitoring techniques
The patient is positioned in the supine position, with legs 
apart resting on straight pads, allowing the surgeon access 
between the legs. The left arm is positioned along the body, 
and the right arm is in abduction at 90° for venous access. A 
forced air system (Bair Hugger™) is placed over the upper 
body. In addition to standard anaesthetic monitoring (elec-
trocardiogram, blood pressure, saturation and temperature), 
depth of  anaesthesia is assessed using a bispectral index, and 
neuromuscular response is closely monitored using a hand 
accelerometer. These parameters must be available to the 
anaesthesiologists outside the OR, either through a window 
or on a second screen. The patient must be kept strictly and 
continuously immobile during the vaporisation. Two periph-
eral venous routes are put in place. The first is used for the 
induction and maintenance of  anaesthesia. The second is 
connected to a long line and is accessible from outside the 
OR if  re-injection is needed.
Before initiating the vaporisation, monitoring, venous access 
and patient positioning must be reassessed, and the surgical 
team goes through the operational safety checklist (online Ap-
pendix 2).
Sedation and curarisation
Propofol is the preferred choice for the induction and mainte-
nance of  anaesthesia, as it reduces postoperative nausea and 
vomiting (PONV) better than volatile anaesthesia. Further-
more, intravenous (i.v.) anaesthesia enables the use of  a closed 
aerosol waste system for exsufflation of  the toxic pneumoperi-
toneum at the end of  the procedure.
Curarisation must last until the end of  the procedure to en-
sure complete patient immobility and constant intra-abdom-
inal pressure with a target post-tetanic count of  between 5 
and 8–10 measured using an automated accelerometer. Ro-
curonium is preferred for its ability to be quickly reversed by 
sugammadex if  needed.
Multimodal pain management
Standard analgesia based on a medium-acting opioid (fentan-
yl) is given to patients for intubation and surgery. A contin-
uous infusion of  lidocaine i.v. is initiated at induction (bolus 
1.5 mg kg-1) and continued (2 mg kg-1 h-1) until departure from 
the recovery room to reduce opioid use and the side effects of  
nausea and vomiting and to optimise postoperative analgesia. 
In addition, patients receive a magnesium sulphate infusion at 
a rate of  40 mg kg-1 over 10 min.
Postoperative analgesia is based on paracetamol, nonsteroidal 
anti-inflammatory drugs and morphine on demand for the 
postoperative period.
Prevention of  PONV
The combination of  general anaesthesia and chemotherapy 
can potentially amplify PONV. Therefore, patients receive an 
association of  three antiemetic drugs: droperidol and dexa-
methasone at the beginning of  the procedure and ondanse-
tron before waking up and for the postoperative period. In 
cases of  intense PONV, fosaprepitant was selected as a rescue 
treatment.
Data management
Demographic, surgical and anaesthetic details for all patients 
were prospectively entered in a computerised, coded database 
designed specifically for the quality control of  the PIPAC co-
hort. Demographic data included age, sex, body mass index, 
American Society of  Anesthesiologists and cancer origins. 
Anaesthetic protocol adherence was analysed with regard to 
the presence of  the dedicated anaesthetic team and the pro-
tocol’s proposed drug usage. Recorded anaesthetic complica-
tions included severe arrhythmia, haemodynamic instability, 
anaphylaxis, mild hypothermia (defined as a temperature 
from 32.2°C to 35.5°C), delayed recovery (>15 min after the 
end of  surgery), difficult i.v. access (defined as needing more 
than two attempts) and moderate to severe pain (defined as 
needing >8 mg of  morphine in the recovery room). For the 
first 74 PIPAC procedures, patients described their pain using 
a visual analogue scale, and the incidence of  PONV was as-
sessed from the recovery room until 72 h and entered in the 
quality control database.
Statistical analysis
Statistical analysis was performed using Stata Software (v. 
14.2; StataCorp, College Station, TX, USA). Continuous 
variables were presented as mean±standard deviation or 
median value with range or interquartile range (IQR), as 
appropriate, depending on the normality of  the distribu-
tion. 
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Results
A median of  2 (1–7) PIPAC treatments was performed on 
our 87 patients, with a total of  193 procedures. The cohort’s 
demographic information is shown in Table 1. The median 
postoperative length of  stay was 2 (IQR 2–3) days.
All surgeries were performed by the same surgeon, 
whereas anaesthesiologists and nurse anaesthetists from 
the dedicated team were present at 79% and 55% of  
procedures, respectively. The overall protocol adherence 
was high with respect to the use of  propofol (100%), ro-
curonium (98%) and multimodal antiemetic prophylaxis 
(99%). Lidocaine perfusion was used in 169 (87%) surgi-
cal procedures and continued until departure from the 
recovery room. Sugammadex had to be used in 52 (27%) 
procedures. 
Anaesthetic complications occurred in 32 (16.5%) pro-
cedures. Twelve (6.3%) patients suffered delayed recov-
ery due to hypothermia (n=7) or excessive sedation or 
curarisation (n=5). Ten (5.2%) patients had mild hypo-
thermia at the end of  the procedure. Other anaesthetic 
complications were 3 difficult intubations, 4 difficult i.v. 
accesses and 10 mild haemodynamic instabilities during 
the laparoscopic phase, requiring low-dose vasopressor 
treatment. 
In the recovery room, moderate to severe pain was document-
ed after 31 (16%) procedures, requiring >8 mg of  morphine 
i.v. and with median doses of  13.7 mg (IQR 8.2–19.2). Me-
dian postoperative pain scores were 1 (IQR 0–4) and 3 (IQR 
0–4) at 12 h and 0 (IQR 0–2) and 0 (IQR 0–3) at 72 h at 
rest and mobilisation, respectively (Figure 2). Symptoms of  
PONV were present in 6.1% of  patients in the recovery room 
and in 40% of  the 25 patients who were still in the hospital at 
72 h (Figure 3). 
No accidental exposure to chemotherapy occurred during the 
study period. Entry to the OR during the vaporisation phase 
was necessary <10 times, principally for anaesthetic pump 
dysfunction.
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Table 1. Patient demographics
No. of  patients 87
Median age, years (IQR) 63 (55–70)
Sex
Male 25 (27.8%)
Female 65 (72.2%)
Median BMI, kg m-2 (IQR) 23.7 (21.2–26.8)
ASA
II 57 (65.5%)
III 30 (34.4%)
Aetiology of  cancer
Ovarian 39 (44.8%)
Colorectal  29 (33.3%)
Gastric 8 (9.2%)
Mesothelioma 4 (4.6%)
Other  7 (8.1%)
Median no. of  PIPAC procedures (range) 2 (1–7)
Median length of  stay, days (IQR, range) 2 (2–3, 1–20)
IQR: interquartile range; BMI: body mass index; ASA: American 
Society of  Anesthesiologists; PIPAC: pressurised intraperitoneal aerosol 
chemotherapy
Figure 3. Postoperative nausea and vomiting (PONV). 
PONV after PIPAC at different time points
Room: recovery room; PIPAC: pressurised intraperitoneal 
aerosol chemotherapy
Figure 2. Pain scores at rest and during mobilisation. 
Evolution of  pain scores over time after a PIPAC proce-
dure, at rest and during mobilisation at different time 
points postoperatively
VAS: visual analogue scale; S.E.M.: standard error of  the mean; 
Room: recovery room
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Discussion
To the best of  our knowledge, this is the first study to analyse 
the anaesthetic management and complications of  patients 
undergoing PIPAC treatment. This surgical technique is spe-
cial because the safety drug protocol requires the remote ad-
ministration of  intraperitoneal chemotherapy, limiting access 
to the patient. By using a dedicated anaesthetic protocol, an-
aesthesia for PIPAC ensured the safety of  patients and health-
care staff, and anaesthetic outcomes were similar to those of  
comparable procedures. 
Pressurised intraperitoneal aerosol chemotherapy is a very 
new type of  treatment, and evidence is so far limited. A first, 
nine-centre, international survey involved 832 procedures on 
349 patients and evaluated the different aspects of  PIPAC 
treatment with respect to surgical methodology. The study 
demonstrated that the procedures were performed the same 
way, probably explained by the standardised procedure and 
the limited number of  expert centres (23). A systematic review 
on PIPAC, published in 2017 by Grass et al. (24), demonstrat-
ed that the procedure was safe and well tolerated. Histological 
response rates for therapy-resistant carcinomatosis of  ovar-
ian, colorectal and gastric origins were promising. Further-
more, our group’s evaluation of  QoL after PIPAC therapy 
demonstrated no negative impact of  the treatment (25).
It has been shown that the safe implementation of  PIPAC was 
possible from the surgical point of  view-even with no learn-
ing curve-when the existing recommendations and protocols 
were followed (20). The requirement to be outside the OR 
and to apply anaesthesia far from the patient is a challeng-
ing scenario, but one which has been described previously, 
for example, in paediatrics with sedation for multiple sessions 
of  radiotherapy (26-28). For the PIPAC procedure, anaesthe-
sia must be given in a potentially toxic environment involving 
cytotoxic drugs. Although no emanations of  cytotoxic agents 
were detected during experimental procedures and no air 
contamination was detectable at the surgeon’s and anaesthe-
siologist’s workstations (29), strict protocols, a safety checklist 
and a dedicated team are mandatory for the safe execution of  
this procedure, including following recommendations on the 
manipulation of  cytotoxic drugs, as for HIPEC procedures 
(30). 
Adherence to the anaesthetic protocol described above was 
high, despite the staff turnover inherent in a teaching institu-
tion. However, a senior anaesthesiologist and referent nurse 
anaesthetist were available on site, in the event of  a problem, 
and the anaesthetic protocol and safety checklist were avail-
able on the department’s intranet. This underscores the im-
portance of  homogenous pathways in maintaining standardi-
sation regardless of  staffing changes.
The overall severity of  surgical complications was mild and 
has already been described by our group. We recorded no mi-
cro-pump injector disconnections or accidental vaporisation 
into the OR air during our series.
By using the recommended protocol, not one major anaes-
thetic complication was observed in 193 procedures. Hypo-
thermia occurred mainly at the beginning of  the study due to 
the initial technical problems with the laparoscopic-gas heat-
er and/or late positioning of  the forced air system and late 
prevention of  hypothermia during anaesthetic induction and 
installation. However, peripheral venous access was challeng-
ing as most patients had few accessible veins due to multiple 
lines of  upfront systemic chemotherapy. Other minor anaes-
thetic problems, such as haemodynamic instability, difficult 
intubation and delayed recovery due to excess sedation or 
curarisation, are inherent to all anaesthetic procedures in a 
teaching hospital and are not related to PIPAC procedures in 
particular.
Lidocaine i.v. was added to optimise pain management, but 
this occurred after the start of  our study programme, thus 
explaining the 87% adherence rate. Pain scores were low 
thanks to a multimodal analgesic approach based on parac-
etamol and nonsteroidal anti-inflammatory drugs, and they 
were similar to those patients undergoing laparoscopic cho-
lecystectomy (31). Only 26 (13.6%) procedures resulted in 
patients requiring morphine i.v. in the recovery room. With 
regard to the 40% of  patients presenting with PONV at 
72 h, only complicated and very frail patients had a hospital 
length of  stay that long, thus explaining this high incidence 
of  PONV.
Conclusion
The anaesthetic management of  patients undergoing PIPAC 
procedures can be performed safely by following the rec-
ommendations within a standardised pathway. Subtle adap-
tations of  standard protocols are necessary to adjust to the 
requirements of  the safety protocol, which includes remote 
administration. Despite this, the anaesthetic management 
and clinical outcomes of  this procedure were comparable 
with operations of  similar invasiveness and duration, such as 
laparoscopic cholecystectomy.
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Recommendations for the anaesthetic management of  pres-
surized intraperitoneal aerosol chemotherapy (PIPAC)
Preoperative assessment
• Preoperative anaesthetic consultation
• Evaluate associated comorbidities, nutritional status, car-
diac, respiratory, renal, hepatic and metabolic functions
• Lab: CBC, Na+, K+, creatinine, urea, fibrinogen, TP, 
PTT, liver tests, albumin
• Know the different neoadjuvant treatments and their side 
effects (haematological and renal toxicity)
• Transfer to room unless a medical or surgical indication 
for continuing care
Admission, layout and positioning in OR   
• Surgical safety checklist (WHO)
• Supine position with legs apart resting on straight pads
• Left arm is positioned along the body, and right arm is in 
abduction at 90° for venous access
• Infusion stand to the right and Bair Hugger™ to the left 
of  the patient
• Check laminar flow is “on”
Drugs to prepare
• Propofol 1% syringe and continuous perfusion, fentanyl, 
rocuronium, succinylcholine and MgSo4
• Prophylactic antibiotic
• If  no contraindication, Xylocaine® IV, bolus at induc-
tion 1.5 mg/kg, then 2 mg/kg/h
• Ephedrine, Neo-Synephrine, atropine
• DHBP, dexamethasone and ondansetron
Equipment
• ECG, BP, saturation, temperature, BIS, neuromuscular 
response with a hand accelerometer
• 2 IV lines on the right arm
• Orogastric tube to remove at the end of  the procedure 
• A forced air system (Bair Hugger™) on the upper body 
• Connection for a closed aerosol waste system through 
two sequential microparticle filters into the anaesthetic 
air waste system 
• High filtration face mask (FFP3), surgical gown, double 
nitrile gloves and protective glasses
Induction and maintenance of  anaesthesia
• Total IV anaesthesia
• Curarisation with rocuronium in bolus or continuous 
perfusion (0.3–0.6 mg/kg/h) with a target post-tetanic 
count (PTC) of  between 5 and 8 to 10
• Fentanyl or sufentanil
• Antibiotics: cefuroxime (Zinacef®) 1.5 g IV (if  allergic, 
refer to local protocol for prophylactic antibiotherapy)
• Magnesium sulphate 40 mg/kg 
• PONV prevention: -at induction: DHBP 1 mg IV, 
Mephameson® 8 mg IV
-at the end of  the procedure: Ondansetron 8 mg IV
Cytostatics
• The surgeon estimates his operating time to coordinate 
the preparation and delivery of  products by the pharma-
cy, usually at the beginning of  the intervention
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• Anaesthetists phone the pharmacy and the carrier to de-
liver the specific products 
Special precautions during the PIPAC phase  
• Protection with surgical gown, non-porous nitrile gloves, 
3M mask with filter and eye protection (protective visor)
• Handling of  cytostatics with non-porous nitrile gloves 
and eye protection
• Elimination of  cytostatic infusions and all material that 
has been in contact with them have to be binned in spe-
cial containers (green)
• Elimination of  the gas and cytostatic products of  the 
pneumoperitoneum by connecting the closed aerosol 
waste system through two sequential microparticle filters 
into the anaesthetic air waste system 
• Negative pressure in operating room throughout the PI-
PAC phase, maximum staff protection
Anaesthesia checklist before vaporisation
Before leaving the room, make sure that:
• Operational safety checklist run-through by surgeons 
• Positioning 
• Ventilation screens, haemodynamics and automated ac-
celerometer visible from outside OR
• Propofol, rocuronium and infusions in sufficient quantity 
for at least 40 min
• Deep curarisation ensured by rocuronium
• Analgesia 
• Safe connection of  the evacuation of  gases
Medical and nursing personnel withdraw from the OR 
during chemotherapy vaporisation, and entry into the oper-
ating room must be avoided unless absolutely necessary.
End of  procedure and waking 
• Paracetamol 1 g IV, ondansetron 8 mg IV
• Standard criteria for awakening and extubation
• If  TOF 0/4 and PTC = 0: wait
• If  TOF 0/4 and PTC > 1: sugammadex 4 mg/kg
• If  TOF 1–3/4 or 4/4 and T4/T1 < 40%: sugammadex 2 mg/kg
• If  TOF 4/4 and T4/T1 > 40%: neostigmine40 µg/
kg(+Robinul®)or sugammadex 1 mg/kg
Cleaning and storage of  the OR 
• All disposable equipment is put in special green contain-
ers (Bair Hugger™, gastric tube, ECG electrodes, BIS, ...)
• Infusions, drugs, syringes in yellow containers
• Do not change the ventilation circuit, however, discard 
the disposable gas suction system in the green container.
• Caution: Do not discard the metallic connection!!!
Recovery room and post-op
• Treatment of  nausea: 
- Ondansetron 3 x 4 mg/day of  office for 2–4 days
- Mephamesone 4 mg 2 x/day in R
- If  persistent nausea despite the above treatment, 
consider Ivemend® = fosaprepitant 150 mg, refrig-
erate. To administer a single dose of  150 mg IV daily 
in combination with ondansetron and mephamesone 
4–12 mg/day
• Antalgics:
- Paracetamol po 4 x 1 g/day
- Morphine IV in the recovery room up to 0.1–0.2 
mg/kg, then sc
- Lidocaine IV to continue at 2 mg/kg/h until exit of  
recovery room 
- Ibuprofen 3x 400 mg/day in R
- Minalgine® IV 4 x 500 mg/day
• Transfer to the surgical department as soon as the trans-
fer criteria have been fulfilled and after the visit of  the 
anaesthesiologist doctor in charge
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